The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Regimex, Didrex
Synonyms :
benzphetamine
Class :
CNS stimulants,Anorexiant
Brand Name :
Regimex, Didrex
Synonyms :
benzphetamine
Class :
CNS stimulants,Anorexiant
Dosage Forms & Strengths
Tablet (Schedule III)
25mg
50mg
Initial dose: 25 to 50mg tablet orally once a day
Maintenance dose: 25 to 50mg tablet orally thrice a day
Dosage Forms & Strengths
Tablet (Schedule III)
25mg
50mg
<12 years: Safety and efficacy not established
>12 years:
Initial dose: 25 to 50mg tablet orally once a day
Maintenance dose: 25 to 50mg tablet orally thrice a day
Refer adult dosing
may increase the hypertensive effect of sympathomimetics
may diminish the excretion of amphetamines
may diminish the excretion of amphetamines
may diminish the excretion of amphetamines
may diminish the excretion of amphetamines
may diminish the excretion of amphetamines
CNS stimulants: they may increase the CNS stimulant effect of opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of non-opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of non-opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of non-opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of non-opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of non-opioid drugs
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
benzphetamine: it may increase the risk of CNS depression
benzphetamine: it may increase the risk of CNS depression
benzphetamine: it may increase the risk of CNS depression
may decrease the therapeutic effect of amphetamines
may decrease the therapeutic effect of amphetamines
may decrease the therapeutic effect of amphetamines
may decrease the therapeutic effect of amphetamines
may decrease the therapeutic effect of amphetamines
may decrease the hypertensive effect of amphetamines
may decrease the hypertensive effect of amphetamines
may decrease the hypertensive effect of amphetamines
may decrease the hypertensive effect of amphetamines
may decrease the hypertensive effect of amphetamines
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
CNS depressants increase the effect of orphenadrine
may diminish the excretion of amphetamines
may diminish the excretion of amphetamines
may diminish the excretion of amphetamines
may diminish the excretion of amphetamines
may diminish the excretion of amphetamines
may decrease the hypertensive effect of amphetamines
may decrease the hypertensive effect of amphetamines
may decrease the hypertensive effect of amphetamines
may decrease the hypertensive effect of amphetamines
may decrease the hypertensive effect of amphetamines
may increase the toxic effect of amphetamines
may increase the toxic effect of amphetamines
may increase the toxic effect of amphetamines
may increase the toxic effect of amphetamines
may increase the toxic effect of amphetamines
may diminish the excretion of amphetamines
may diminish the excretion of amphetamines
may diminish the excretion of amphetamines
may diminish the excretion of amphetamines
may diminish the excretion of amphetamines
may increase the serum concentration of amphetamines
may increase the serum concentration of amphetamines
may increase the serum concentration of amphetamines
may increase the serum concentration of amphetamines
may increase the serum concentration of amphetamines
may increase the toxic effect of sympathomimetics
may increase the toxic effect of amphetamines
may diminish the serum concentration of amphetamines
may diminish the serum concentration of amphetamines
may diminish the serum concentration of amphetamines
The potential for increased CNS depression risk or seriousness occurs when benzphetamine is used together with pipecuronium
When benzphetamine is used together with bromisoval, the risk or seriousness of CNS depression is enhanced
When captodiame is used together with benzphetamine, There is a risk or seriousness of CNS depression is enhanced
When benzphetamine is used together with medazepam, the risk or seriousness of CNS depression is enhanced
The potential for CNS depression may enhanced when benzphetamine is used together with fencamfamine
When benzphetamine is used together with niaprazine, the risk or seriousness of CNS depression is enhanced
When domeperidone and benzphetamine is used together, this leads to reduction in the domeperidone’s metabolism
When benzphetamine is used together with fluconazole, this leads to reduction in the benzphetamine metabolism
When chlordiazepoxide is used together with benzphetamine, this leads to enhanced risk or seriousness of CNS depression
When emylcamate is used together with benzphetamine, this leads to enhanced risk or seriousness of CNS depression
When benzphetamine is used together with etizolam, this leads to enhanced risk or seriousness of CNS depression
When benzphetamine is used together with bismuth subnitrate, this leads to an enhanced concentration serum of benzphetamine
benzphetamine: it may increase the risk or severity of CNS depression
benzphetamine: it may increase the risk or severity of CNS depression
benzphetamine: it may increase the risk or severity of CNS depression
benzphetamine: it may increase the risk or severity of CNS depression
benzphetamine: it may increase the risk or severity of CNS depression
When benzphetamine is used in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
benzphetamine: it may decrease the therapeutic efficacy of moxisylyte
benzphetamine's serum concentration may increase when combined with almasilate
When benzphetamine is used together with diazoxide, this leads to reduction in diazoxide’s antihypertensive effects
may increase the risk or severity of hypertension when combined
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
benzphetamine reduces sedation while papaverine increases it
metyrosine: they may increase the sedative effect of CNS stimulants
pegvisomant: they may increase the sedative effect of CNS stimulants
ramosetron: they may increase the sedative effect of CNS stimulants
opioid drugs: they may increase the sedative effect of CNS stimulants
opioid drugs: they may increase the sedative effect of CNS stimulants
opioid drugs: they may increase the sedative effect of CNS stimulants
opioid drugs: they may increase the sedative effect of CNS stimulants
combining benzphetamine with decamethonium increases the risk of CNS depression
the CNS depression risk or severity may be increased when benzphetamine is combined with remacemide
pipotiazine: it may decrease the stimulatory activities of benzphetamine
the risk of hypertension may be increased
When benzphetamine is used together in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
Mechanism of action
CNS stimulation:
benzphetamine stimulates the central nervous system (CNS) by increasing the release of norepinephrine and dopamine in the brain and blocking their reuptake. This increases these neurotransmitters’ levels in the synaptic cleft, leading to increased CNS stimulation and decreased appetite.
Sympathetic nervous system activation: benzphetamine also stimulates the sympathetic nervous system, causing an increase in heart rate, blood pressure, and respiratory rate
Spectrum
Appetite suppression: The primary use of benzphetamine is as a weight loss aid due to its appetite-suppressing effects
CNS stimulation: benzphetamine also has CNS-stimulating effects, which can result in increased alertness, focus, and energy levels
Frequency undefined:
Increased blood pressure
Diarrhea
Dry mouth
Insomnia
Libido changes
Palpitations
Restlessness
Tremor
Abdominal pain
Constipation
Dizziness
Headache
Nausea
Tachycardia
Psychotic episodes
Contraindications
Caution
Pregnancy consideration:
Contraindicated
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology
benzphetamine is a stimulant medication that belongs to the phenethylamine class of drugs. It increases the release of certain neurotransmitters, including norepinephrine, dopamine, and serotonin, in the brain. This increases activity in the central nervous system (CNS), leading to increased alertness, decreased appetite, and improved focus and attention
Pharmacodynamics
The pharmacodynamics of benzphetamine is complex and not fully understood, but it is believed to work by increasing the release of neurotransmitters, such as norepinephrine, dopamine, and serotonin, in the brain. The increased release of these neurotransmitters results in increased activity in the CNS, leading to increased alertness, decreased appetite, and improved focus and attention. Additionally, benzphetamine may inhibit the reuptake of these neurotransmitters, thereby prolonging their effects and enhancing their availability in the synaptic cleft
Pharmacokinetics
Absorption
benzphetamine is rapidly absorbed from the gastrointestinal tract after oral administration, with its onset of action typically occurring within one hour. The oral bioavailability of benzphetamine is approximately 90%, meaning that a large proportion of the dose is absorbed into the bloodstream
Distribution
benzphetamine is distributed throughout the body and rapidly reaches its site of action in the brain. It has a high volume of distribution, meaning that it rapidly spreads throughout the body and is found in a high concentration in the blood
Metabolism
benzphetamine is metabolized in the liver, primarily by the CYP2D6 enzyme. It is converted into several inactive metabolites, which are then excreted in the urine. The metabolism of benzphetamine may be altered in individuals with genetic variations in the CYP2D6 enzyme, leading to differences in its pharmacokinetics and potential interactions with other medications
Elimination/Excretion
Most benzphetamine and its metabolites are excreted in the urine, with a small portion excreted in the feces. The elimination half-life of benzphetamine is approximately 8 hours, meaning it takes approximately 8 hours for half of the dose to be eliminated from the body
Administration
Dosage: The recommended dose of benzphetamine for weight loss is 30 mg to 50 mg, taken three times a day, approximately 30 minutes before meals. The recommended dose for ADHD is 30 mg to 60 mg, taken once or twice a day, with or without food
Timing: benzphetamine is taken 30 minutes before meals for weight loss and once or twice a day for ADHD. It is essential to take benzphetamine simultaneously each day to maintain a consistent level of the medication in the body
Food Interactions: benzphetamine can be taken with or without food, although it may be more effective on an empty stomach. Taking benzphetamine with a high-fat meal may decrease its absorption and effectiveness.
Alcohol Interactions: Alcohol should be avoided while taking benzphetamine as it may increase the risk of adverse effects such as increased heart rate and blood pressure. The recommended dose of benzphetamine for weight loss is 30 mg to 50 mg, taken three times a day, approximately 30 minutes before meals. The recommended dose for ADHD is 30 mg to 60 mg, taken once or twice a day, with or without food
Patient information leaflet
Generic Name: benzphetamine
Pronounced: [ benz-FET-ah-meen ]
Why do we use benzphetamine?
benzphetamine is a stimulant medication primarily used for weight loss and attention deficit hyperactivity disorder (ADHD)
Weight Loss: benzphetamine is used as an appetite suppressant to treat obesity. It works by increasing the release of neurotransmitters, such as norepinephrine, dopamine, and serotonin, which can help to decrease appetite and increase feelings of fullness
ADHD: benzphetamine treats attention deficit hyperactivity disorder (ADHD) in adults and children. It works by increasing the release of neurotransmitters, such as norepinephrine and dopamine, which can help to improve focus and attention and decrease impulsiveness and hyperactivity
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
